Influenza A Virus, H1N1 Subtype

Displaying 1 - 2 of 2CSV
Tenforde, M. W., Weber, Z. A., DeSilva, M. B., Stenehjem, E., Yang, D.-H., Fireman, B., Gaglani, M., Kojima, N., Irving, S. A., Rao, S., Grannis, S. J., Naleway, A. L., Kirshner, L., Kharbanda, A. B., Dascomb, K., Lewis, N., Dalton, A. F., Ball, S. W., Natarajan, K., … Klein, N. P. (2023). Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network. The Journal of Infectious Diseases, 228(2), 185–195. https://doi.org/10.1093/infdis/jiad015
Publication Date
Gao, R., Wang, Z., Uprety, T., Sreenivasan, C. C., Sheng, Z., Hause, B. M., Brunick, C., Wu, H., Luke, T., Bausch, C. L., Sullivan, E. J., Hoppe, A. D., Huber, V. C., Wang, D., & Li, F. (2023). A fully human monoclonal antibody possesses antibody‐dependent cellular cytotoxicity (ADCC) activity against the H1 subtype of influenza A virus by targeting a conserved epitope at the HA1 protomer interface. Journal of Medical Virology, 95(7). Portico. https://doi.org/10.1002/jmv.28901
Publication Date